Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.54 |
| ▸ | CTSB | P07858 | 7/20 | 0.49 |
| ▸ | CTSS | P25774 | 7/20 | 0.49 |
| ▸ | CTSL | P07711 | 5/20 | 0.46 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.44 |
| ▸ | HSPA2 | P54652 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 4/20 | 0.41 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.39 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5444152 | 0.88 | TRPV4 (0.59) | TRPV4CTSBCTSSCTSLCTSK | |
| SCHEMBL5431334 | 0.86 | TRPV4 (0.73) | TRPV4CTSBCTSSCTSKUTS2R | |
| SCHEMBL4136396 | 0.83 | TRPV4 (0.70) | TRPV4CTSBCTSSCTSLCTSK | |
| SCHEMBL5429305 | 0.83 | TRPV4 (0.63) | TRPV4CTSBCTSSCTSLCTSK | |
| SCHEMBL5434009 | 0.83 | TRPV4 (0.53) | TRPV4CTSBCTSSCTSLCTSK | |
| SCHEMBL5435992 | 0.82 | TRPV4 (0.52) | TRPV4CTSBCTSSCTSLCTSK | |
| SCHEMBL3914861 | 0.81 | TRPV4 (0.44) | TRPV4LMNAALDH1A1HTT | |
| SCHEMBL5446781 | 0.80 | TRPV4 (0.51) | TRPV4CTSBCTSSCTSLCTSK | |
| SCHEMBL5434744 | 0.80 | TRPV4 (0.56) | TRPV4CTSBCTSSCTSLCTSK | |
| SCHEMBL5441701 | 0.79 | TRPV4 (0.57) | TRPV4CTSBCTSSCTSLCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | claimed |
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | disclosed |
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | disclosed |
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | TRPV4, TRPC4, TRPV1 | TRPV4 1/4885CTSB 3229/4885CTSS 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.